- Conditions
- Irritable Bowel Syndrome
- Interventions
- Eluxadoline, Placebo
- Drug
- Lead sponsor
- Furiex Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 807 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 288
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 225 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 67
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- BEKINDA, Placebo
- Drug
- Lead sponsor
- RedHill Biopharma Limited
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 16
- States / cities
- Huntsville, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 12 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Medical Food, Placebo
- Other
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- Ibodutant 10 mg, Placebo
- Drug
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 73
- States / cities
- Chandler, Arizona • Glendale, Arizona • Mesa, Arizona + 62 more
- Conditions
- Irritable Bowel Syndrome With Diarrhea (IBS-D)
- Interventions
- DNK333, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 180 participants
- Timeline
- 2006 – 2007
- U.S. locations
- 37
- States / cities
- Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Olorinab, Placebo
- Drug
- Lead sponsor
- Arena Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Non-Constipation Irritable Bowel Syndrome
- Interventions
- Rifaximin, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 88
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 83 more
- Conditions
- IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
- Interventions
- rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo
- Drug
- Lead sponsor
- Mark Pimentel, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Irritable Bowel, Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome Mixed, Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome Without Diarrhea, Irritable Bowel Syndrome Aggravated, Irritable Bowel Syndrome Characterized by Constipation, Irritable Bowel Syndrome Characterised by Alternating Bowel Habit
- Interventions
- No intervention
- Other
- Lead sponsor
- ProgenaBiome
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Ventura, California
- Conditions
- Diarrhea Predominant Irritable Bowel Syndrome
- Interventions
- Asimadoline, Placebo
- Drug
- Lead sponsor
- Tioga Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 142
- States / cities
- Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 125 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Probiotic
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Houston, Texas • Seattle, Washington
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Placebo, BMS-562086
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Blautix, Placebo
- Biological · Other
- Lead sponsor
- 4D pharma plc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 24
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • North Hollywood, California + 21 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- DDP225
- Drug
- Lead sponsor
- Dynogen Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • St Louis, Missouri • Great Neck, New York + 2 more
- Conditions
- Diarrhea-predominant Irritable Bowel Syndrome
- Interventions
- Serum-derived bovine immunoglobulin protein isolate (SBI)
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- ORP-101, Placebo
- Drug
- Lead sponsor
- OrphoMed, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
- Conditions
- Diarrhea-Predominant Irritable Bowel Syndrome
- Interventions
- Glutamine
- Drug
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Eluxadoline, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 26
- States / cities
- Hot Springs, Arkansas • Little Rock, Arkansas • Corona, California + 19 more
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- Placebo, Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 20
- States / cities
- Sherwood, Arkansas • Anaheim, California • Sacramento, California + 17 more
- Conditions
- Irritable Bowel Syndrome, Diarrhea
- Interventions
- LY3537031, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 15
- States / cities
- Mesa, Arizona • Anaheim, California • Lancaster, California + 12 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- 25mg Eluxadoline, 100mg Eluxadoline
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 6
- States / cities
- Corona, California • Miami, Florida • Stockbridge, Georgia + 2 more
- Conditions
- Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome With Mixed Bowel Habits
- Interventions
- Dietary Intervention
- Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Dextofisopam
- Drug
- Lead sponsor
- Pharmos
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- 0.075 mg RVX-100, 0.125 mg RVX-100, 0.250 mg RVX-100, placebo
- Drug
- Lead sponsor
- Revogenex, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Chevy Chase, Maryland